Garry Nolan - 01 Jun 2023 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Garry Nolan, Ph.D., by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
01 Jun 2023
Transactions value $
$0
Form type
4
Filing time
05 Jun 2023, 17:36:40 UTC
Previous filing
27 Mar 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKYA Stock Option (Right to Buy) Award $0 +56,322 $0 56,322 01 Jun 2023 Common Stock 56,322 $5.7 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Subject to the reporting person's continuous service through the vesting date, the options shall vest in full on the earlier of (a) June 1, 2024, or (b) the date of the next annual meeting of Akoya Biosciences, Inc. occurring after the date of grant.